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Kidney transplantation is clearly the preferred treatment of end stage kidney disease since it 
allows for a nearly normal life quality and is in the long run considerably cheaper than 
maintenance dialysis. National and international data unambiguously show that great success 
have been achieved over the last years in prolonging patient and graft survival after kidney 
transplantation. However most of the improvement can be attributed to the increased one year 
graft function due to better pre-transplant risk evaluation such risk stratification by preformed 
anti-donor HLA antibodies (DSAs or donor specific antibodies), technical planning of the 
surgical procedure in live donor transplantation, postoperative care and improved 
immunosuppressive regimen.  
 
However, the incidence of post-transplantation acute renal failure (ARF), the one early 
clinical condition with the strongest negative impact on survival, remained virtually 
unchanged over the years. ARF eventually resolves after some days but delayed allograft 
function (DGF) affects roughly 25% of all recipients of deceased donor transplants but 
virtually never in live donor transplants. This highly prevalent condition in deceased donor 
transplantation represents the main risk factor for a reduced allograft survival. Studies showed 
that kidney transplants with DGF have a more than doubled risk for graft loss compared to 
matched transplants with primary or immediate graft function. These facts clearly show that 




The main goal of the PhD studies was to elucidate the molecular pathways and subsequent 
clinical predictors of ARF/DGF in experimental and clinical studies. Furthermore, the causal 
inference of the findings should be tested in a RCT of renal allograft recipients and thus 
allowing for novel clinical management strategies of such patients.  
 





Extensive in vitro and in vivo experiments of ARF/DGF as well as clinical RCTs were 
performed in the context of this thesis. A schematic overview of this work plan is illustrated 
in figure 1. 
 
 
Figure 1. Work plan for the study of ARF experimentally and in the human post-transplant 
setting (LCM … laser capture microdissection; QC … quality control; OEDTR … 
Österreichisches Dialyse and Transplant Registry; POC … proof of concept) 
 
To assess the associations of morphologic and molecular features in the human deceased 
donor kidneys, pre-implantation biopsies were obtained in large amounts in order to have a 
sufficient number of outcomes, i.e. cases of ARF, which occur in roughly 25% of deceased 
donor kidney transplants. A collaboration with the Semmelweis University Clinic in Budapest 
was initiated since in this excellent transplant center roughly 200 kidney transplants are 
performed annually. Together with the Medical University of Vienna and the Elisabethinen 
hospital in Linz, we had access to over 400 renal transplants per year. The post-transplant 
course was monitored and recorded into a web-based database. 
Materials & Techniques 
A detailed description of all methodological utilized in this research may be found at the 
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In brief, the following techniques were used in the research projects: 
• Affymetrix mRNA and miRNA arrays 
• cDNA Arrays 
• Cell culture 
• ELISA 
• Immunohistochemistry 
• Peptide Arrays 
• Protein concentration 
• qRT - PCR 
• Western blotting 
A detailed description of the animal experiments may be found at the respective sections of 
this paper. 
Systems Biology 
The integrative analyses using a systems biology approach was carried out in collaboration 
with Bernd Mayer and coworkers from emergentec (www.emergenetc.com). Emergentec has 
developed an in silico network of molecular processes and interactions between protein 
coding features derived from various omics tracks and published literature that mirror the 
physiological dependencies. The annotated relations network holds 18,000 vertices, 800,000 
edges on which the expression profiles of the donor kidneys are superimposed (figure 2). 
 
 
Figure 2. Schematic representation of the molecular network ‘omicsNET’  
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Discovery and Validation Studies 
After the transcriptomics studies, cDNA and miRNA arrays were conducted on the same 
biopsies in a novel prospective cohort of renal allograft recipients with the aim to uncover the 
complex molecular regulation of ARF in further depth. The sample size of 122 donors were 
chosen to obtain roughly the same representative numbers of ARF and BCAR follow up 
biopsies in the first week and a half after transplantation. Ten protocol biopsies without ARF 
and BACR were taken in the same period and served as control tissue. 
 
4. Results 
ARF Specific Molecular Network 
Based on the available omics profiles an ARF specific network was defined and subsequently 
superimposed on the omicsNET and segmented. The significant features and 
dependencies/interactions between the nodes are displayed in figure 3. Most of the 
differentially regulated features in the ARF kidneys belong to the gene ontologies of 
inflammation, immunity and host defence, some were transcription factors. 
 
 
Figure 3. Inflammation network in donor kidneys which subsequently developed post-
transplant ARF. The colour code refers to the gene ontologies of the individual features. 
 
The interpretation of the transcriptomics findings is unambiguously that inflammation in the 
kidneys occurs in the deceased donor before the organs are harvested.  
The observed inflammatory signals in the donor kidneys with post-transplant ARF however 
were derived from observational studies and thus can only be considered as associational 
finding. The proof of causality of inflammation as determinant of ARF thus could only be 
conducted in an interventional study. Therefore, we designed and conducted a RCT to test 
whether the treatment of inflammation in the donor causes a reduction of the incidence of 
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post-transplant ARF/DGF. DGF is the primary endpoint was defined as the need for more 
than one post-transplant dialysis. A finer resolution of the potential effect was the duration of 
DGF and the number of dialysis session required.  
In this blinded multicentre trial 207 deceased donors were randomized to 1000mg of 
methylprednislon or placebo single shot injection three to six hours before the organ retrieval. 
Preimplantation biopsies were obtained to test whether the randomization, timing and dose of 
the intervention (1000mg methylprednislon) was appropriately chosen to reduce the 
inflammation cascade on a genome wide level in the kidneys. The biopsies were subjected to 
microarray testing and the post-transplant course was monitored.  
The CONSORT flow chart (http://www.consort-statement.org/) of the conducted study is 
illustrated in. 
The transcriptomics experiments on randomly selected 20 biopsies, 10 of each intervention 
group (steroid/placebo) were conducted on cDNA microarrays holding 41,421 features (batch 
SHEO) from the Stanford University Functional Genomics core facility. The steroid pre-
treatment of the donors led to a reduction of many features of the inflammation cascades and 
activation of metabolism genes. Based on these data we were confident that the coordination, 
timing, dosing and intervention of this blinded and logistically challenging worked fine.  
Despite the global suppression of inflammation in the donor organs by steroid treatment, the 
incidence of DGF was 22 and 25% respectively and thus not different between groups.  
Accordingly, the resolution of DGF as indicated by creatinine trajectories remained 
unchanged after donor steroid treatment (figure 4). 
 
 
Figure 4. Trajectories of post-transplant creatinine by randomization group. The p-value 
refers to the F-test in the mixed linear model for longitudinal data. 
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Effect of Steroid Donor Treatment on other Transplanted Organs 
Steroid pre-treatment did not effect on the incidence of rejections or mortality. Furthermore, 
the trajectories of the transaminases showed no impact in the degree of peri-transplant liver 
injury by steroid pre-treatment. 
The miRNA Discoveries 
Since it became clear that the suppression of inflammation in the donor organs was not 
sufficient to change the early outcomes ARF/DGF after engraftment, novel approaches were 
investigated assuming that other contributors than inflammation were causally responsible for 
initiation and maintenance of ARF leading to DGF after transplantation. In order to cover a 
wider range of regulatory target pathways than steroid treatment could accomplish, the 
microRNA (miRNA) expression in the organs at risk of ARF were determined.  
A recent summary of the genesis of miRNA, their contribution to pathologies in the transplant 
kidney as well as potential therapeutic applications may be found in the review by J. 
Wilflingseder et al. 
The simultaneous analysis of mRNA and miRNA transcripts in the ARF compared to 
protocol biopsies yielded several features that remained statistically significant after 
adjustment for multiple testing using the SAM false discovery rate <10% penalization. The 
significant features of both analyses in aggregate form are displayed in figure 5. 
 
 
Figure 5. Molecular features discriminating DGF from primary graft kidney biopsies 
according to their p-value of significance.  
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The prediction of miRNA targets was performed by a web-based custom computational 
algorithm that allows the integration of all available routines and individual adjustment of the 
significance threshold. This algorithm coined miRway is accessible on my lab-website at 
http://mirway.nephrogene.at/MirWayFrontend/faces/start.xhtml 
We identified miR-182-5p as the best discriminator between DGF and primary patency. 
Target candidate proteins were identified and showed many proteins that have been presented 
to be involved in ARF regulation by cell cycle regulation and repair such as cycle regulators 
such as PCNA, cdc2, cdk4 or clock and transcription factors such as FOXO3.  
Clinical Applicability and Utility 
Previous studies showed that small oligonucleotides and siRNAs can exhibit antisense 
activity in the kidney. Acute renal failure was induced in SD rats by right uninephrectomy 
and clamping of the left renal artery for 40 minutes. Rats were pretreated 12 hours before 
insult with either anatgomiR-182 (ASO 2.5 and 25mM) or equal concentrations of 
mismatched antisense oligonucleotides. Intrarenal expression of miR-182 remained 
selectively reduced in the antagomiR treated rats. 
The trajectories of serum creatinine were determined daily for seven days after the injury. 
Histological evaluation of kidney was performed on days two and seven after insult. 
AntagomiR-182 (ASO) treatment led to an amelioration of the functional and morphological 
insult as evidence in figures 6. 
 
Figure 6. Trajectories of serum creatinine over the first seven days after ischemia reperfusion 
injury in rats. ASO low refers to an anti-miR concentration of 2.5mM or equal concentrations 
of mismatched control. 
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After investigations from cell culture to whole animal experiments showed that anti-miR-182 
selectively inhibited miRNA-182 activity and activation of target proteins as well as 
amelioration of IRI in the rat models, we proceeded with studies of anti-miR-182 in ex vivo 
perfused pig kidneys. Freshly harvested pig kidneys were subjected to ex vivo normothermic 
machine perfusion with UW solution (University of Wisconsin) solution at a pressure of 
80mmHg. 
Quantitative PCR of the biopsies from the pig kidney showed a selective inhibition of miR-




The work of the last decade focused on the molecular pathways of ischemia reperfusion injury 
in human kidney transplantation. The work plan was carefully designed and experiment 
meticulously planned. The projects were continuously supported since 1996 by Austrian 
research grants (FWF) and EU-grants. In summary my research group nephrogene showed 
that inflammation in the donor organ is highly predictive of DGF after transplantation. 
Suppression of this inflammatory process in the donor ameliorated inflammation on a genome 
wide level but did not change the incidence of DGF. Thus new avenues were chosen to tackle 
this important enigma. Antisense oligonucleotide constructs against miRNAs were 
investigated by systems biology approaches and lead identified also experimentally. The top 
candidate – antagomiR-182 – was able to suppress the target miR selectively also ex - and in 
vivo and led to inhibition of the suppression of miR-182 target proteins such as Bcl-2 or 
FOXO-1. This molecular intervention led functionally to a reduced severity of IRI as 
evidenced by creatinine trajectories in rat models and improved histopathology of the IRI 
kidneys.  
We are confident that the application of our approach to human kidney transplantation is 
feasible and will lead to a clinical breakthrough in the treatment of acute renal failure in the 
transplant but eventually also in native kidneys of patients suffering from acute renal failure 
in the ICU.  
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